At 16.3% CAGR, the Europe T Cell Therapy Market is Projected to be Worth US$ 2,345.49 million by 2030, says Business Market Insights

According to Business Market Insights’ research, the Europe T cell therapy market was valued at US$ 699.24 million in 2022 and is expected to reach US$ 2,345.49 million by 2030, registering a CAGR of 16.3% from 2022 to 2030. Growing burden of cancer worldwide and increasing number of approvals of t-cell therapies are among the critical factors attributed to the Europe T cell therapy market expansion.             

Globally, companies operating in the T-cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investment, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few noteworthy developments in the T-cell therapy market are mentioned below.

In August 2023, Astellas invested US$ 50 million in Poseida’s CAR T-cell therapy. Astellas will have exclusive negotiation and first refusal for licensing P-MUC1C-ALLO1 in solid tumors as part of the agreement. P-MUC1C-ALLO1 is an allogeneic CAR T-cell therapy targeting cancer-specific Mucin 1 protein (MUC1-C) forms. It is currently under investigation in an open-label multicentre Phase I clinical trial (NCT05239143) treating multiple epithelial-derived solid tumor indications. In May 2023, Laurus Labs’ stake in ImmunoACT will now increase to 33.86% on a fully diluted basis post completion of the deal. The company had already acquired 26.62% of stakes in ImmunoACT in November 2021. ImmunoACT has a portfolio of CAR T-cell therapy assets under various development stages for treating multiple autoimmune diseases and oncology indications. This investment further strengthens Laurus Labs’ commitment to accessing novel Cell and Gene Therapy technology and enhances its affordability for patients. This investment will further help ImmunoACT to gear up for the manufacture of more treatments. In November 2021, Autolus Therapeutics plc (a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies) and Blackstone Life Sciences entered into a strategic collaboration and financing agreement under which funds managed by Blackstone will provide up to US$ 250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as the next-generation product therapies of obe-cel in B-cell malignancies. Thus, these investments create lucrative opportunities in the Europe T-cell therapy market.

On the contrary, side-effects of CAR T-cell therapy hampers on the growth of Europe T cell therapy market. 

Based on modality, the Europe T cell therapy market is bifurcated into research and commercialized. The commercialized segment held 89.8% market share in 2022, amassing US$  628.03 million. It is projected to garner US$  2,153.22 million by 2030 to expand at 16.7% CAGR during 2022–2030.

Based on therapy type, the Europe T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held 95.3% share of Europe T cell therapy market in 2022, amassing US$ 666.04 million. It is projected to garner US$ 2,275.14 million by 2030 to expand at 16.6% CAGR during 2022–2030.

Based on indication, the Europe T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held 95.3% share of Europe T cell therapy market in 2022, amassing US$ 666.04 million. It is projected to garner US$ 2,275.14 million by 2030 to expand at 16.6% CAGR during 2022–2030.

Based on country, the Europe T cell therapy market has been categorized into Germany, UK, France, Italy, Spain, the Rest of Europe. Our regional analysis states that Germany captured 31.0% share of Europe T cell therapy market in 2022. It was assessed at US$ 216.92 million in 2022 and is likely to hit US$ 773.96 million by 2030, exhibiting a CAGR of 17.2% during 2022–2030.            

Key players operating in the Europe T cell therapy market are Bristol-Myers Squibb Co, Gilead Sciences Inc, Immunocore Holdings Plc, Innovent Biologics Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG, among others.

• May 2022: Legend Biotech Corporation announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com